TickerFacts.

MBX Biosciences, Inc. (MBX): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.93M
Year ended 2025-12-31
$2.53M
Trailing 12 months to 2026-06-30
2023-12-31: $129.0K2024-12-31: $874.0K2025-12-31: $1.93M$1.93M
2023-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.93M+120.7%2026-03-12, From 2025-01-01
2024-12-31$874.0K+577.5%2026-03-12, From 2024-01-01
2023-12-31$129.0Kn/a2025-03-17, From 2023-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
MBX Biosciences, Inc. (MBX)2025-12-31$1.93M+120.7%
Zenas BioPharma, Inc. (ZBIO)2025-12-31$18.0K-86.3%
Entrada Therapeutics, Inc. (TRDA)2025-12-31$1.04M-67.0%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$291.0K+781.8%
Erasca, Inc. (ERAS)2025-12-31$128.0K+113.3%
Ironwood Pharmaceuticals Inc (IRWD)2025-12-31$34.0K-76.1%
Tango Therapeutics, Inc. (TNGX)2025-12-31$1.05M+39.0%
Harrow, Inc. (HROW)2025-12-31$887.0K-44.4%
Nkarta, Inc. (NKTX)2025-12-31$1.21M-72.6%

Compare MBX, ZBIO, TRDA, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗